Achieve Life Sciences Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +3.4% | -52.8% | -64.0% | +92.9% | +10.4% | +91.2% | +17.9% | -36.9% | -35.4% | +99.4% | +8.2% | |
| – | +4.2% | -52.8% | -78.3% | +163.0% | +11.6% | +113.3% | +20.6% | -38.7% | -37.9% | +114.7% | +9.4% | |
| – | +23.0% | -55.6% | -65.3% | +80.1% | +75.1% | +115.2% | +20.0% | -42.5% | -37.1% | -18.1% | +64.4% | |
| – | +17.2% | -53.6% | -79.5% | +177.3% | +13.7% | +115.2% | +20.0% | -42.5% | -37.1% | +120.9% | +6.0% | |
| – | -97.8% | +308.0% | -98.2% | -22.2% | +14.3% | – | – | -31.4% | +5.7% | – | – | |
| – | – | – | – | -122.5% | – | – | – | – | – | – | – | |
| – | +134.2% | -57.1% | -77.1% | -40.7% | +62.9% | -26.3% | +52.4% | +98.4% | – | – | – | |
| – | – | +0.0% | +99,900.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | – | -7.5% | +91,805.6% | -8.8% | -9.7% | -10.7% | -12.0% | -13.6% | -15.6% | -18.6% | -22.9% | |
| – | -6.6% | -59.1% | -76.3% | +63.0% | -7.7% | -0.5% | +546.5% | +11.3% | -3.9% | -14.8% | +14.3% | |
| – | -7.0% | -59.1% | -76.2% | +62.4% | -12.3% | +2.3% | +55.0% | +374.7% | -3.6% | -67.9% | +35.9% | |
| – | -89.0% | +1,603.8% | -97.0% | -59.3% | +1,745.5% | -54.7% | -25.0% | +23,275.4% | +3.7% | -99.7% | +6,745.5% | |
| – | +1,765.3% | +57.9% | -90.0% | -32.4% | +496.5% | -61.4% | +153.3% | +97.4% | -62.8% | +215.5% | -55.5% | |
| – | – | -53.3% | -100.0% | – | – | – | – | +7.7% | – | – | +13.7% | |
| – | +9.9% | -49.3% | -58.5% | +100.6% | +14.2% | +106.6% | -24.8% | -70.4% | -117.4% | – | +3.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +44.5% | +14.8% | +75.7% | +632.2% | +134.9% | +559.4% | +198.6% | +30.5% | +87.2% | +61.8% | +35.9% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.